MINK Therapeutics Reports Significant Clinical Progress

Introduction

MINK THERAPEUTICS INC (NASDAQ: INKT) is a clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts. The firm specializes in allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies targeting oncology and immune-mediated disorders. As of July 11, 2025, MINK shares closed at $22.61 on the NASDAQ, reflecting a 192.50% increase over the referenced period, with trading volume at 2,509,155 shares.

Corporate Structure

Founded in 2017, MINK Therapeutics employs between 11 and 50 staff across research, development, and operations. The leadership team is led by President and Chief Executive Officer Dr. Jennifer Buell. The company utilizes a proprietary manufacturing platform for large-scale, reproducible production of donor-derived iNKT cells, which is designed to streamline global distribution.

iNKT therapy by Pretty Drugthings

Developments and News

On March 18, 2025, MINK reported fourth quarter and full year 2024 results. Financial highlights included:

• A year-end cash balance of $4.6 million, compared with $3.2 million reported at the first quarter 2025 filing.
• Cash used in operations of $1.7 million in Q4 2024 and $9.6 million for the full year, versus $3.0 million and $15.8 million in 2023.
• A net loss of $10.8 million for 2024, or $2.86 per share, narrowing from a $22.5 million loss, or $6.54 per share, in 2023.

Clinical and strategic milestones featured:

• Presentation of Phase 1/2 data for AGENT-797 (native iNKT cells) at AACR IO and SITC 2024, indicating enhanced checkpoint inhibitor efficacy in advanced gastric cancer cohorts.
• Publication in Nature Communications and an ATS presentation of AGENT-797’s immunologic activity in acute respiratory distress syndrome (ARDS), showing an 80% survival rate in VV ECMO patients compared to 10% in historical controls.
• Advancements in next-generation candidates, including PRAME-TCR iNKT cells with specific tumor targeting and IL-15 armored MiNK-215 CAR-iNKT cells demonstrating activity in metastatic colorectal cancer models.
• Entry into a research collaboration with Autonomous Therapeutics in October 2024 to develop precision RNA-iNKT therapies for metastatic tumors.
• A case study published in Oncogene in June 2025 reported a response in metastatic, refractory testicular cancer treated with AGENT-797 plus anti–PD-1 therapy.
• Award of a grant from the National Institute of Allergy and Infectious Diseases (NIAID) in June 2025 to support the development of allo-iNKT therapy aimed at reducing graft-versus-host disease in stem cell transplant patients.

Financial and Strategic Analysis

As of its May 15, 2025 10-Q filing, MINK reported no revenue for the trailing twelve months and a TTM EPS of –$2.46. Market capitalization stood near $30.2 million, with $3.23 million in cash at quarter-end and negative levered free cash flow of $7.59 million. The company raised $5.8 million in private financing during 2024 and prioritizes externally funded clinical studies.

Strategically, MINK focuses on scaling its allogeneic iNKT platform. The manufacturing process is designed to yield billions of cells per run, aiming to lower costs and logistical complexity compared with autologous approaches. Collaborations and grant-funded research are intended to extend the pipeline into immune-mediated indications and engineered iNKT modalities.

Market Position and Industry Context

MINK operates in the expanding field of off-the-shelf cell therapies, where allogeneic products offer reduced time-to-treatment compared to patient-derived autologous cells. Competitors include firms developing CAR-T and NK cell therapies, but MINK’s iNKT platform targets both solid tumors and inflammatory conditions, differentiating on tissue targeting and graft-versus-host disease suppression. Upcoming IND filings for FAP-CAR and BCMA-CAR iNKT candidates in 2024 and 2025 are expected to further establish the company in the cell-therapy sector.

tl;dr

MINK Therapeutics reported a net loss of $10.8 million for 2024, narrowed from $22.5 million in 2023, supported by a cash balance of $4.6 million at year-end and $5.8 million in private financing during 2024. Clinical progress includes Phase 1/2 data for AGENT-797 in gastric cancer and ARDS presentations in March 2025, a June 2025 case study in Oncogene for refractory testicular cancer, and planned IND filings for FAP-CAR and BCMA-CAR iNKT programs in 2025. Ongoing collaborations and a NIAID grant aim to extend applications into immune-mediated disorders, while the firm prepares for scaled manufacturing for global off-the-shelf delivery.